Tocilizumab Therapy and Incident Depression in Rheumatoid Arthritis: A Retrospective Cohort Study of the All of Us Research Program
Steven Lehrer, Peter Rheinstein · 2026
Read Tocilizumab Therapy and Incident Depression in Rheumatoid Arthritis: A Retrospective Cohort Study of the All of Us Research Program by Steven Lehrer, Peter Rheinstein (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13525739.txt.
Description
Lehrer and Rheinstein asked if a drug for rheumatoid arthritis might also cut the risk of new depression. Their 2026 study used the All of Us health records scheme in the United States. It covered 9,826 adults with the joint disease who had no past record of depression. Of these, 299 took tocilizumab, a drug that blocks a body signal that drives swelling. The rest did not take the drug.
New depression arose in about twenty-two of each hundred who took the drug. In the group that did not, the rate was about thirty-five of each hundred. The gap held when the team weighed age, sex, and race, and when it used time-based checks. The team is careful to say this link does not prove the drug caused the gain. It calls for trials that test the drug for mood in a direct way.
Catalog record
| CREATOR | Steven Lehrer, Peter Rheinstein |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |